Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michela Forti"'
Autor:
Eleonora Marchina, Michela Forti, Mariella Tonelli, Stefania Maccarini, Francesca Malvestiti, Chiara Piantoni, Elena Filippini, Elisa Fazzi, Giuseppe Borsani
Publikováno v:
Molecular Cytogenetics, Vol 14, Iss 1, Pp 1-8 (2021)
Abstract Background Small supernumerary marker chromosomes (sSMC) are a heterogeneous group of structurally abnormal chromosomes, with an incidence of 0,044% in newborns that increases up to almost 7 times in developmentally retarded patients. sSMC f
Externí odkaz:
https://doaj.org/article/60680abd01ed4a68bb010ea73d146dc3
Autor:
Chiara Piantoni, Stefania Maccarini, Francesca Malvestiti, Elena Filippini, Eleonora Marchina, Elisa Fazzi, Giuseppe Borsani, Michela Forti, Mariella Tonelli
Publikováno v:
Molecular Cytogenetics, Vol 14, Iss 1, Pp 1-8 (2021)
Molecular Cytogenetics
Molecular Cytogenetics
Background Small supernumerary marker chromosomes (sSMC) are a heterogeneous group of structurally abnormal chromosomes, with an incidence of 0,044% in newborns that increases up to almost 7 times in developmentally retarded patients. sSMC from all 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1998e2d23ff8c1e49000b9d2868751e
https://doaj.org/article/60680abd01ed4a68bb010ea73d146dc3
https://doaj.org/article/60680abd01ed4a68bb010ea73d146dc3
Autor:
Laura Zanotti, Alfredo Berruti, Michela Forti, Maria Rosa Cappelletti, Vito Amoroso, Manuela Milani, Sandra Sigala, Mario Martinotti, Edda Simoncini, Daniele Generali, Francesca Bedussi, Mara Ardine, Alberto Bottini, Carla Strina
Publikováno v:
Journal of the National Cancer Institute. Monographs. 2015(51)
Breast cancer represents a heterogeneous group of diseases with varied biological features, behavior, and response to therapy; thus, management of breast cancer relies on the availability of robust predictive and prognostic factors to support therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bccd3d031c0376256537b09b7b12036a
https://pubmed.ncbi.nlm.nih.gov/26063883
https://pubmed.ncbi.nlm.nih.gov/26063883
Autor:
Giulia Brugnoli, Mara Ardine, Laura Zanotti, Maria Rosa Cappelletti, Maria Elena Vailati, Daniele Generali, Ramona Bertoni, Sergio Aguggini, Adrian L Harris, G Allevi, Giuseppina Ferrero, Alfredo Berruti, Alberto Bottini, Carla Strina, Francesca Bedussi, Manuela Milani, Michela Forti, Stephen B. Fox
INTRODUCTION: Recently the combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus and the aromatase inhibitor exemestane has been shown to double the progression-free survival rate in advanced breast cancer. However, the effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62a98c535b03c23c891737deeb457fc9
http://hdl.handle.net/11368/2903815
http://hdl.handle.net/11368/2903815
